An Opioid Abuse-Deterrent Roadmap for the Pharmaceutical Industry

|

article image
Since 1999, the quantity of prescription opioids sold in the United States has nearly quadrupled, resulting in an average of 650,000 opioid prescriptions dispensed daily. Deaths from prescription opioids—drugs like oxycodone, hydrocodone, and methadone—have also quadrupled, causing more than 165,000 deaths in the U.S. within a 15-year time period (1999-2014). Additionally, an estimated 1.9 million people in the United States suffer from substance use disorders related to prescription opioid pain medicines.1 How much is the abuse epidemic costing the nation? It has been established that the health and social costs related to prescription opioid abuse total more than $55 billion each year, including $20 billion in emergency room and inpatient care for opioid poisonings.

Spotlight

Enable Injections, Inc.

Enable Injections is pioneering a new class of drug delivery technology, the wearable high-volume injector, that industry experts are calling “truly revolutionary.” Winner of Buzz of BIO Investor Forum and other accolades, the Enable Injections technology is designed to allow easy, comfortable self-administration of the more than 900 high volume, viscous biologics in development--promising new drugs to treat a host of conditions from cancers and autoimmune diseases to genetic and rare diseases that, because of the large doses required, cannot be delivered with today’s legacy injection technology. Founded in 2010 by medical device industry veterans, the company has R&D and manufacturing facilities in Franklin, Ohio.

OTHER ARTICLES

As Pandemic Continues, Rafael Pharmaceuticals Enrolls Patients in Phase III Pancreatic Cancer Trial

Article | April 17, 2020

That simple truth about the severity of the disease is one of the reasons that Rafael Pharmaceuticals is slowly continuing with a Phase III trial in metastatic pancreatic cancer during the COVID-19 pandemic. While many companies have paused enrollment in clinical trials during the outbreak, Cranbury, N.J,-based Rafael opted to continue to enroll patients in its Phase III AVENGER 500 study of its lead compound CPI-613 (devimistat) in combination with modified Folfirinox (mFFX) as first-line therapy for the disease. Sanjeev Luther, president and chief executive officer of Rafael Pharmaceuticals, told BioSpace that the company made the decision to continue to enroll the trial, which was 75% filled, due to the short timeline patients with metastatic pancreatic cancer have. After discussing the matter of the trial with the company’s leadership team, Luther said they felt comfortable leaving the decision of whether or not the trial should continue to the conducting institute.

Read More

Advance Your Pharma Supply Chain Planning during a Pandemic

Article | April 17, 2020

One predominant and common element within our pharmaceutical industry, is our devotions to patients. Within supply chain there is always a focus on ensuring the right product is delivered to the right place at the right time in order to ensure patient safety and the continuity of medicinal supplies. With the spread of COVID-19 across 117 countries and counting, every supply chain needs to evaluate their global footprint and develop contingency plans within their end to end operations.

Read More

5 Pharma Trends and Their Impact on Packaging

Article | April 17, 2020

The pharmaceutical industry is changing at an unprecedented pace. New biological treatments for cancer, and a dramatic rise of widespread diseases such as diabetes, call for new processing and packaging solutions to fulfill the different needs all over the world. Keep your eye on these five main packaging trends for 2020 for the global pharmaceutical market.

Read More

Top Specialty Pharmacy Therapy Areas

Article | April 17, 2020

Accelerated by advancements in cancer treatments and a growing emphasis on personalized and precision medicine, specialty pharmacy represents a rapidly growing sector within the healthcare industry. In fact, the market is projected to grow to $500 billion by the end of this year—up from $200 billion in total U.S. specialty drug spending in 2017. Industry growth of this magnitude creates challenges for those looking to understand and penetrate the market. It can be difficult, after all, to maintain updated information about high-priority drug therapy areas or facility affiliations in a market that’s constantly changing.

Read More

Spotlight

Enable Injections, Inc.

Enable Injections is pioneering a new class of drug delivery technology, the wearable high-volume injector, that industry experts are calling “truly revolutionary.” Winner of Buzz of BIO Investor Forum and other accolades, the Enable Injections technology is designed to allow easy, comfortable self-administration of the more than 900 high volume, viscous biologics in development--promising new drugs to treat a host of conditions from cancers and autoimmune diseases to genetic and rare diseases that, because of the large doses required, cannot be delivered with today’s legacy injection technology. Founded in 2010 by medical device industry veterans, the company has R&D and manufacturing facilities in Franklin, Ohio.

Events